with Element one of a new generation of rivals alongside the likes of PacBio and Singular Genomics, which launched their Onso and G4 instruments in 2022 and 2021, respectively. Element’s Series ...

Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a significant ...

Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...

In the last three months, 4 analysts have published ratings on Pacific Biosciences PACB, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97.

HO CHI MINH CITY, VIETNAM, Mar 6, 2025 - (ACN Newswire) - analytica Vietnam 2025, the country's largest and most influential trade fair for laboratory technology, analysis, and biotechnology, is set t ...